Dicot AB

06/10/2022 | Press release | Distributed by Public on 06/10/2022 01:52

Dicot: Dicot moves forward with a new patent application

Press release from Companies

Publicerat: 2022-06-10 09:45:00

Dicot AB: Dicot moves forward with a new patent application

Press release: Uppsala, June 10, 2022. Dicot AB is developing the drug candidate LIB-01, a potency drug to better treat erectile dysfunction and premature ejaculation. The company announces that it is now moving forward with a new patent application in order to extend the patent protection around the company's drug candidate until at least 2042.

Dicot is developing a new potency drug that aims to be the first choice for the treatment of erectile dysfunction and premature ejaculation. At the beginning of 2022, Dicot announced that several new patent opportunities were identified and that they would be protected as trade secrets, in order to convert these into patents at the right point of time. The goal of the strategy is to ensure the longest possible market exclusivity and revenue opportunity for LIB-01 and thereby the shareholder value.

Dicot today announces that the company will proceed with one of these trade secrets and that a new patent application is being prepared. The purpose is to patent both new manufacturing methods and intermediates (various chemical compounds) during the manufacture of the drug substance in Dicot's product candidate LIB-01. The patent application will be submitted after the summer. Patents provide 20 years of market exclusivity from the time the application is submitted.

"Dicot's IP-portfolio is already a unique asset in the billion market for sexual dysfunctions and with additional new patents we will significantly increase the long-term value of our product candidate through market exclusivity until at least 2042. This means we execute according to plan, based on our IP strategy. ", says Elin Trampe, CEO of Dicot.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.